Fundraising Fox
Ambergen
Watertown, US · Founded 2022 · Delaware corporation
Find your way into Ambergen
251 people in our graph share verified history with the Ambergen team — schools, employers, funds. One of them is your warm intro.
William Woounlockedknows Kenneth Rothschild · together at Boston University (overlapped)
×11knows the team · via Boston University
AmberGen operates the MaxOmic Laboratory, offering multiomic spatial biology imaging and analysis services along with probes, panels, and antibody conjugation kits based on its patented photocleavable mass-tag technology. It serves researchers, drug developers, and clinicians in the life sciences and biotech sector.
Founders & leadership
Ambergen was founded in 2022 by Kenneth Rothschild.
KR
Kenneth RothschildFounder · Chairman of the BoardKenneth Rothschild is Emeritus Professor of Physics at Boston University and Executive Chairman and Chief Innovation Officer at AmberGen, a spatial biology company. He holds a Ph.D. in Physics from MIT and co-invented photocleavable mass tags for mass spectrometry-based protein imaging in tissues.
ME
Michael EasterlingNamed on SEC filing
JG
John GillespieNamed on SEC filing
PF
Peter FinnNamed on SEC filing
BR
Brian RothschildNamed on SEC filing
Reported raises · per SEC filings
Form D private placements$5M disclosed across 1 round · 2022
▶$5MraisedApr 2022 · 1 investors · BiotechnologyRule 506(b)
▶$5MraisedApr 2022 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michael EasterlingDirector
- Kenneth RothschildExecutive Officer, Director
- John GillespieExecutive Officer, Director
- Peter FinnExecutive Officer
- Brian RothschildDirector
- Offering amount
- $5M
- Amount sold
- $5M
- Minimum investment
- $5M
- First sale
- Apr 2022
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 50+ SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2022 | $2.4M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2022 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2022 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2020 | $2.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2019 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2018 | $1.9M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2018 | $300K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2016 | $2.3M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2016 | $225K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2014 | $3M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2014 | $999.5K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2012 | $1.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2012 | $698.4K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2012 | $596.9K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2012 | $199.8K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2011 | $299.7K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2010 | $3M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2010 | $188.2K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2009 | $1.6M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2009 | $187.2K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2008 | $1.3M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2007 | $848.9K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2007 | $657.6K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2007 | $383.3K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2007 | $381.9K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2006 | $1.4M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2006 | $749.8K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2006 | $749K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2006 | $187.1K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2006 | $154.2K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2005 | $187.3K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2005 | $183.9K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2005 | $150K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2004 | $749.9K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2004 | $599.9K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2004 | $187K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2004 | $121.7K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2004 | $100K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2004 | — |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2003 | $599.5K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2003 | $100K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2002 | $599.7K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2002 | $100K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2002 | $99.9K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2001 | $549.2K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2001 | $388.4K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2001 | $98.4K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2001 | — |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2001 | — |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2000 | $372.7K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Ambergen do?
- AmberGen operates the MaxOmic Laboratory, offering multiomic spatial biology imaging and analysis services along with probes, panels, and antibody conjugation kits based on its patented photocleavable mass-tag technology. It serves researchers, drug developers, and clinicians in the life sciences and biotech sector.
- Who founded Ambergen?
- Ambergen was founded by Kenneth Rothschild in 2022.
- How much funding has Ambergen raised?
- Ambergen has disclosed $5M raised across 1 round.
- Where is Ambergen headquartered?
- Ambergen is headquartered in Watertown, US.